Glucocorticoid receptor agonist and immunoconjugates thereof
US-2018126000-A1 · May 10, 2018 · US
Cyclodextrin protein drug conjugates
US11491237B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11491237-B2 |
| Application number | US-201815975191-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 9, 2018 |
| Priority date | May 18, 2017 |
| Publication date | Nov 8, 2022 |
| Grant date | Nov 8, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided herein are compounds, compositions, conjugates and methods for the treatment of diseases, and/or conditions such as, but not limited to, proliferative diseases. In certain embodiments, compounds, compositions, and conjugates are provided, which include cyclodextrin-based linker-payloads and protein conjugates thereof, and/or in combination with other agents. By administering these compounds, compositions, and conjugates as described herein to specific target cells, side-effects due to non-specific binding phenomena, for example, to non-target cells are reduced.
First claim
Opening claim text (preview).
What is claimed is: 1. A compound, or a pharmaceutically acceptable salt thereof, wherein the compound (i) is according to formula (Ib1), (Ib2), or (Ic1): (ii) is according to a formula selected from:…
Assignees
Inventors
Classifications
Chemistry & Metallurgy · mapped topic
Human Necessities · mapped topic
- A61K47/61Primary
Human Necessities · mapped topic
- A61K47/6807Primary
Human Necessities · mapped topic
Chemistry & Metallurgy · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11491237B2 cover?
- Provided herein are compounds, compositions, conjugates and methods for the treatment of diseases, and/or conditions such as, but not limited to, proliferative diseases. In certain embodiments, compounds, compositions, and conjugates are provided, which include cyclodextrin-based linker-payloads and protein conjugates thereof, and/or in combination with other agents. By administering these comp…
- Who is the assignee on this patent?
- Regeneran Pharmaceuticals Inc, Regeneron Pharma
- What technology area does this patent fall under?
- Primary CPC classification A61K47/61. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Nov 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).